SCHEMBL4703036

SCHEMBL4703036

CN1CCN(c2ccc(NC=C3C(=O)Nc4cc(C(=O)c5cccc(NC(=O)Nc6ccccc6)c5)ccc43)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.56
NTRK1 P04629 4/20 0.47
NTRK3 Q16288 1/20 0.47
FLT3 P36888 5/20 0.46
KDR P35968 2/20 0.46
AURKA O14965 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
NTRK2 Q16620 3/20 0.45
KIT P10721 2/20 0.45
FLT4 P35916 2/20 0.45
PDGFRB P09619 1/20 0.45
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
ESR2 Q92731 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
AURKB Q96GD4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4759327 1.00 CSF1R (0.56) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4755254 0.95 CSF1R (0.54) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4755255 0.95 CSF1R (0.54) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4703897 0.94 CSF1R (0.54) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4758624 0.94 CSF1R (0.54) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4706534 0.94 CSF1R (0.53) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4757149 0.94 CSF1R (0.53) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4757933 0.94 NPC1 (0.52) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4757936 0.94 NPC1 (0.52) CSF1RNTRK1NTRK3FLT3KDR
SCHEMBL4703858 0.93 CSF1R (0.52) CSF1RNTRK1NTRK3FLT3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 CSF1R 877/4885NTRK1 413/4885NTRK3 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.